Tarsus Pharmaceuticals Inc. logo

Tarsus Pharmaceuticals Inc.

TARS | NASDAQ
Chart Builder DCF Calculator
$77.46
-$0.63 (-0.81%)
At close: Sep 21, 2026, 4:00 PM ET
$77.46
$0 (0.00%)
After-hours: Sep 21, 2026, 7:30 PM ET

Market Data

Market Cap
$3.36B
Enterprise Value
$2.88B
Beta
0.54
Average Volume
914.09K
Shares Outstanding (Diluted)
43.39M
Shares Change YoY
2.44%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US87650L1035

Price Performance

Price Change 1M
6.1%
Price Change 3M
17.1%
Price Change 6M
15.7%
Price Change YTD
-4.1%
Price Change 1Y
39.2%
Price Change 3Y
357.0%
Price Change 5Y
240.0%
1M CAGR (ann.)
19.5%
1Y CAGR (ann.)
51.1%
5Y CAGR (ann.)
28.5%
All-Time CAGR
25.2%

Valuation

PE Ratio
-71.06
Forward PE
28.07
PEG Ratio
-0.86
Forward PEG
0.41
PS Ratio
5.50
Forward PS
3.70
PB Ratio
9.61
P/FCF Ratio
54.15
P/Adj. FCF Ratio
342.37
P/OCF Ratio
42.10
EV/Sales
4.75
EV/EBIT
-76.77
EV/EBITDA
-81.87
EV/FCF
46.84
Earnings Yield
-1.4%
FCF Yield
1.9%
Adj. FCF Yield
0.3%

Financial Health

Net Cash
$449.69M
Total Debt
$0
Cash & Short-Term Investments
$449.69M
Total Assets
$611.14M
Current Ratio
3.20
Quick Ratio
3.17
Debt / Equity Ratio
0.26
Debt / EBITDA
-0.00
Debt / FCF
0.00
OCF / Debt
N/A
Interest Coverage
-5.63
Altman Z-Score
8.14
Piotroski F-Score
5

Margins & Profitability

Gross Profit Margin
90.6%
Operating Profit Margin
-8.0%
EBITDA Margin
-5.8%
Net Profit Margin
-7.7%
FCF Margin
10.2%
Adj. FCF Margin
1.6%
SBC / Revenue
8.6%
SBC Impact (per share)
-84.2%

Returns

Return on Assets
-7.6%
Return on Equity
-13.5%
Return on Invested Capital
-11.2%
Return on Capital Employed
-11.2%
Return on Tangible Assets
-7.7%

Historical Growth (CAGR)

Revenue CAGR 3Y
264.7%
Revenue CAGR 5Y
61.4%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
64.4%
EPS CAGR 5Y
15.4%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
184.0%
FCF CAGR 5Y
31.5%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
10
EPS Growth Next 3Y
226.6%
Revenue Growth Next 3Y
27.9%
Earnings Date
Nov 2, 2026
EPS Estimate (next Q)
-$1.43
EPS Growth Est (next Q)
376.7%
Revenue Est (next Q)
$183.75M
Revenue Growth Est (next Q)
54.8%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$100.40
Price Target Upside
29.6%

Cash Flow

Operating Cash Flow
$79.7M
Free Cash Flow
$61.55M
Adj. Free Cash Flow
$9.73M
FCF Per Share
$1.42
OCF Per Share
$1.84
OCF/S Ratio
13.1%

Income Statement

Revenue
$606.33M
Gross Profit
$549.3M
Operating Income
$-48.54M
EBITDA
$-35.22M
Net Income
$-46.48M
EPS (Diluted)
-$1.09
Revenue / Employee
$1.64M
Profit / Employee
$-125.61K
Employees
370

© 2026 bestshares.com. All rights reserved.